Skip to main content
. 2024 Feb 1;6(1):vdae014. doi: 10.1093/noajnl/vdae014

Table 2.

Adverse Events

Adverse events*, n (%) Total (n = 24)
All Grades Grade 3 or 4
Any adverse events 23 (95.8) 6 (25)
General and constitutional events
 Nausea 12 (50)
 Fatigue 10 (41.7)
 Anorexia 9 (37.5)
 Weight loss 5 (20.8)
 Muscle weakness 4 (16.7)
 Dehydration 3 (12.5)
 Fall 3 (12.5)
 Fever 2 (8.3)
 Arthralgia 2 (8.3)
 Allergic rhinitis 2 (8.3)
Hematologic events
 Thrombocytopenia 7 (29.2) 3 (12.5)
 Hypokalemia 5 (20.8) 1 (4.2)
 Neutropenia 4 (16.7) 4 (16.7)
 Lymphocytopenia 3 (12.5) 2 (8.3)
 Anemia 2 (8.3) 2 (8.3)
 Low bicarbonate 2 (8.3)
 Hyperchloremia 2 (8.3)
Gastrointestinal events
 Constipation 6 (25)
 Diarrhea 5 (20.8)
 Vomiting 5 (20.8)
 Dysphagia 4 (16.7) 1 (4.2)
 Dysgeusia 2 (8.3)
 Xerostomia 2 (8.3)
Cardiovascular events
 Thromboembolic event 4 (16.7) 1 (4.2)
 Hypertension 4 (16.7)
 Extremity edema 2 (8.3)
 Extremity pain 2 (8.3)
Genitourinary events
 Urinary frequency 5 (20.8)
 Urinary tract infection 3 (12.5) 1 (4.2)
Dermatologic events
 Urticaria 2 (8.3)
Neurologic and psychiatric events
 Paresthesia 11 (45.8)
 Confusion 7 (29.2) 2 (8.3)
 Memory impairment 6 (25)
 Seizure 5 (20.8) 1 (4.2)
 Insomnia 5 (20.8)
 Headache 4 (16.7)
 Tremor 4 (16.7)
 Agitation 3 (12.5)
 Dysphasia 3 (12.5) 1 (4.2)
 Dysesthesia 3 (12.5)
 Gait disturbance 3 (12.5)
 Aphasia 3 (12.5)
 Tinnitus 2 (8.3)
 Hallucinations 2 (8.3)
 Cognitive disturbance 2 (8.3)

Note: *Data only include events occurring at >5% frequency for all adverse event grades.

There were no recorded Grade 5 adverse events.

Among the aggregated cases of Grade 3 or 4 thrombocytopenia, 2 cases were Grade 3 and 1 was Grade 4. Among the aggregated cases of Grade 3 or 4 neutropenia, 2 cases were Grade 3 and 2 cases were Grade 4.